الفهرس 
Introduction& RationaleOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
B-cell lymphomas are malignant neoplasms that arise from various stages of B-cell differentiation and span a wide spectrum, ranging from small- to large-cell types and from low to high clinical behavior grades. It is the most common type of non-lymphoma. Hodgkin’s diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for 30-40% of newly diagnosed malignant lymphoma cases.
Fibrinogen is a plasma glycoprotein produced primarily by liver cells, but also by epithelial and tumor cells. It is concerned with platelet aggregation, coagulation, and wound healing on a physiological level. Fibrinogen is one of the positive acute phase proteins, which have elevated levels during inflammation.
The connection between tumorgenesis and the inflammatory process is clear. The inflammatory microenvironment of tumor cells is an important part of the neoplastic process because it maintains a high proliferative rate, long-term survival signals, and tumor cell migration. By binding to inflammatory or neoplastic cells, fibrinogen stimulates the production of proinflammatory cytokines. Furthermore, fibrinogen promotes neoplastic cell proliferation, invasion, and metastasis by inducing sustained adhesion of neoplastic cells and promoting the formation of tumor new vessels by fibroblast growth factor beta.
The study aimed to assess plasma fibrinogen level in patients with B-cell lymphoma and determine the difference between its level before and after treatment.